Latest news with #Generics
Business Standard
28-07-2025
- Business
- Business Standard
Laurus Labs climbs on robust Q1 earnings
Laurus Labs jumped 6.44% to Rs 892.05 after the company's consolidated net profit zoomed 1,154% to Rs 163 crore, driven by a 31% rise in net sales to Rs 1,570 crore compared to Q1 June 2024. Gross margin improved to 59.4% in Q1 June 2025, up from 55.1% in Q1 June 2024. Profit before tax (PBT) stood at Rs 224 crore for Q1 June 2025, reflecting a 1,144% increase over Q1 June 2024. EBITDA was Rs 389 crore in Q1 June 2025, up 127% compared to Q1 June 2024. EBITDA margin rose to 24.8%, up from 14.3% in Q1 June 2024. In Q1 FY26, Laurus Labs Contract Development and Manufacturing Operations (CDMO) revenue more than doubled year-on-year to Rs 522 crore, driven by a 130% increase in small molecules revenue, although the bio-segment saw a 33% decline. Revenue from the Generics division rose 12% to Rs 1,048 crore, with APIs dipping 4% but finished dosages (FDF) surging 50%. Additionally, ARV revenues advanced 17% to Rs 647 crore during the period under review. Dr. Satyanarayana Chava, founder & chief executive officer commented: "We made healthy progress to start the year with increasing contributions from CDMO business and continued advancement of pipeline projects, supported by Generic FDF. We are moving ahead with strong focus on commercial execution realizing the full potential from promising pipeline opportunities, business development and rapidly enhancing scale and technology capabilities. We also commenced construction of various facilities across CDMO, Generics and FDF. Once complete, these facilities will fortify our ongoing commitment of being a high-quality development and manufacturing partner at scale including advanced therapies. We remain confident in our strategic direction and commitment as the source of sustainable value creation now and well into the future." V V Ravi Kumar, executive director & chief financial officer commented: "We delivered a solid performance in Q1, in line with expectations. We are pleased to see sustained growth momentum fueled by increasing uptake in CDMO deliveries and healthy business fundamentals. The EBITDA margins improved substantially to 24.8%, supported by continuing operating leverage. Gross margins stood strong at 59.4% due to favorable CDMO mix and ongoing process improvement initiatives. We will continue to invest fully behind high value business opportunities to drive near and long-term growth and returns for our shareholders." Meanwhile, the Government of Andhra Pradesh has allotted 531.77 acres of land in IP Rambilli Phase-II, Anakapalli District, to the company for the establishment of Laurus Pharma Zone (LPZ), where it plans to set up manufacturing units for pharmaceutical products. Laurus Labs has earmarked an investment of Rs 5,630 crore for this project, which is expected to generate employment for 6,350 people in three phases over eight years. This land allotment marks a significant milestone, securing a crucial component for the companys future expansion plans. Laurus Labs is a research-driven pharmaceutical and biotechnology company. It develops and manufactures select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. It offers end-to-end CDMO services, supporting innovators from early-stage development to commercial production.
Economic Times
07-05-2025
- Business
- Economic Times
Buy Biocon, target price Rs 351: Axis Securities
Agencies Biocon's key products/revenue segments include Bio Pharmaceuticals, Other Operating Revenue, Waste and Sale of services for the year ending 31-Mar-2024. Financials For the quarter ended 31-12-2024, the company has reported a Consolidated Total Income of Rs 3856.20 crore, up 6.44% from last quarter Total Income of Rs 3622.90 crore and down -14.67 % from last year same quarter Total Income of Rs 4519.20 crore. The company has reported net profit after tax of Rs 81.10 crore in the latest quarter. The company?s top management includes Mazumdar Shaw, Robert Haggar, Mehrotra Menon, Lal Kidwai, Kanubhai Parikh, Damodaran, Vivek Mazumdar, Rasendra Mazumdar, Mittal, Dhawan. The company has B S R & Co. LLP as its auditors. As on 31-03-2025, the company has a total of 120 Crore shares outstanding. Live Events Investment Rationale Biosimilars are continuously gaining market share across the geographies. Launching products like gLiraglutide in Generics and a strong pipeline of upcoming Biosimilars like Stellara and YESFILI provides a strong outlook for business in the upcoming quarters. The industry is continuously supporting the Biocon Business. The brokerage recommends a BUY with a target price of Rs 351, which implies an upside of 10% from the current market price (CMP). Promoter/FII Holdings Promoters held 60.64 per cent stake in the company as of 31-Mar-2025, while FIIs owned 5.67 per cent, DIIs 15.72 per cent. (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Axis Securities has a Buy call on Biocon with a target price of Rs 351. The current market price of Biocon is Rs 339.45. The time period given by the analyst is Half-yearly when Biocon price can reach the defined target. Biocon, incorporated in 1978, is a Large Cap company with a market cap of Rs 40538.26 crore, operating in the Pharmaceuticals key products/revenue segments include Bio Pharmaceuticals, Other Operating Revenue, Waste and Sale of services for the year ending the quarter ended 31-12-2024, the company has reported a Consolidated Total Income of Rs 3856.20 crore, up 6.44% from last quarter Total Income of Rs 3622.90 crore and down -14.67 % from last year same quarter Total Income of Rs 4519.20 crore. The company has reported net profit after tax of Rs 81.10 crore in the latest company?s top management includes Mazumdar Shaw, Robert Haggar, Mehrotra Menon, Lal Kidwai, Kanubhai Parikh, Damodaran, Vivek Mazumdar, Rasendra Mazumdar, Mittal, Dhawan. The company has B S R & Co. LLP as its auditors. As on 31-03-2025, the company has a total of 120 Crore shares are continuously gaining market share across the geographies. Launching products like gLiraglutide in Generics and a strong pipeline of upcoming Biosimilars like Stellara and YESFILI provides a strong outlook for business in the upcoming quarters. The industry is continuously supporting the Biocon Business. The brokerage recommends a BUY with a target price of Rs 351, which implies an upside of 10% from the current market price (CMP).Promoters held 60.64 per cent stake in the company as of 31-Mar-2025, while FIIs owned 5.67 per cent, DIIs 15.72 per cent. (Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
